{"id":2929,"date":"2019-03-25T13:00:00","date_gmt":"2019-03-25T13:00:00","guid":{"rendered":"https:\/\/www.xvivogroup.com\/us\/mfn_news\/rattelse-av-kallelse-till-arsstamma-i-xvivo-perfusion-ab-publ\/"},"modified":"2019-03-25T13:00:00","modified_gmt":"2019-03-25T13:00:00","slug":"rattelse-av-kallelse-till-arsstamma-i-xvivo-perfusion-ab-publ","status":"publish","type":"mfn_news","link":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/rattelse-av-kallelse-till-arsstamma-i-xvivo-perfusion-ab-publ\/","title":{"rendered":"R\u00c4TTELSE AV KALLELSE TILL \u00c5RSST\u00c4MMA I XVIVO PERFUSION AB (publ)"},"content":{"rendered":"<p><span>Den 20 mars 2019 offentliggjorde XVIVO Perfusion AB (publ) kallelse till \u00e5rsst\u00e4mma torsdagen den 25 april 2019. Vid angivandet av avst\u00e4mningsdag f\u00f6r deltagande vid st\u00e4mman samt sista anm\u00e4lningsdag f\u00f6r deltagande vid st\u00e4mman angavs felaktigt fredagen den 19 april 2019 respektive m\u00e5ndagen den<\/span> <span>22 april 2019. Avst\u00e4mningsdag har korrigerats till onsdagen den 17 april 2019 och sista anm\u00e4lningsdag till tisdagen den 23 april 2019.<\/span><\/p>\n<p><span>Kallelsen till \u00e5rsst\u00e4mman \u00e4r i \u00f6vrigt of\u00f6r\u00e4ndrad. Den r\u00e4ttade kallelsen bifogas som bilaga och finns \u00e4ven tillg\u00e4nglig p\u00e5 bolagets hemsida: <\/span><span><a href=\"http:\/\/www.xvivoperfusion.com\" rel=\"nofollow\">www.xvivoperfusion.com<\/a><\/span>\u00a0<\/p>\n<div class=\"mfn-footer\">\n<p><span>Fr\u00e5gor h\u00e4nvisas till:<\/span><br \/><span>G\u00f6sta Johannesson, styrelsens ordf\u00f6rande, +46 8-614 00 20, gosta.johannesson@bure.se<\/span><br \/><span>Christoffer Rosenblad, CFO, +46 735 192159, christoffer.rosenblad@xvivoperfusion.com<\/span><\/p>\n<p><span>Informationen l\u00e4mnades f\u00f6r publicering den\u00a025 mars 2019 kl. 14:00.<\/span><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Den 20 mars 2019 offentliggjorde XVIVO Perfusion AB (publ) kallelse till \u00e5rsst\u00e4mma torsdagen den 25 april 2019. Vid angivandet av&#8230;<\/p>\n","protected":false},"template":"","class_list":["post-2929","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-lang-sv","mfn-news-tag-mfn-regulatory","mfn-news-tag-mfn-regulatory-listing","mfn-news-tag-mfn-ci","mfn-news-tag-mfn-ci-gm","mfn-news-tag-mfn-ci-gm-notice"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>R\u00c4TTELSE AV KALLELSE TILL \u00c5RSST\u00c4MMA I XVIVO PERFUSION AB (publ) - XVIVO<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/rattelse-av-kallelse-till-arsstamma-i-xvivo-perfusion-ab-publ\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"R\u00c4TTELSE AV KALLELSE TILL \u00c5RSST\u00c4MMA I XVIVO PERFUSION AB (publ) - XVIVO\" \/>\n<meta property=\"og:description\" content=\"Den 20 mars 2019 offentliggjorde XVIVO Perfusion AB (publ) kallelse till \u00e5rsst\u00e4mma torsdagen den 25 april 2019. Vid angivandet av...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/rattelse-av-kallelse-till-arsstamma-i-xvivo-perfusion-ab-publ\/\" \/>\n<meta property=\"og:site_name\" content=\"United States\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/rattelse-av-kallelse-till-arsstamma-i-xvivo-perfusion-ab-publ\\\/\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/rattelse-av-kallelse-till-arsstamma-i-xvivo-perfusion-ab-publ\\\/\",\"name\":\"R\u00c4TTELSE AV KALLELSE TILL \u00c5RSST\u00c4MMA I XVIVO PERFUSION AB (publ) - XVIVO\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\"},\"datePublished\":\"2019-03-25T13:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/rattelse-av-kallelse-till-arsstamma-i-xvivo-perfusion-ab-publ\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/rattelse-av-kallelse-till-arsstamma-i-xvivo-perfusion-ab-publ\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/rattelse-av-kallelse-till-arsstamma-i-xvivo-perfusion-ab-publ\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"R\u00c4TTELSE AV KALLELSE TILL \u00c5RSST\u00c4MMA I XVIVO PERFUSION AB (publ)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\",\"name\":\"United States\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"R\u00c4TTELSE AV KALLELSE TILL \u00c5RSST\u00c4MMA I XVIVO PERFUSION AB (publ) - XVIVO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/rattelse-av-kallelse-till-arsstamma-i-xvivo-perfusion-ab-publ\/","og_locale":"en_US","og_type":"article","og_title":"R\u00c4TTELSE AV KALLELSE TILL \u00c5RSST\u00c4MMA I XVIVO PERFUSION AB (publ) - XVIVO","og_description":"Den 20 mars 2019 offentliggjorde XVIVO Perfusion AB (publ) kallelse till \u00e5rsst\u00e4mma torsdagen den 25 april 2019. Vid angivandet av...","og_url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/rattelse-av-kallelse-till-arsstamma-i-xvivo-perfusion-ab-publ\/","og_site_name":"United States","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/rattelse-av-kallelse-till-arsstamma-i-xvivo-perfusion-ab-publ\/","url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/rattelse-av-kallelse-till-arsstamma-i-xvivo-perfusion-ab-publ\/","name":"R\u00c4TTELSE AV KALLELSE TILL \u00c5RSST\u00c4MMA I XVIVO PERFUSION AB (publ) - XVIVO","isPartOf":{"@id":"https:\/\/www.xvivogroup.com\/us\/#website"},"datePublished":"2019-03-25T13:00:00+00:00","breadcrumb":{"@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/rattelse-av-kallelse-till-arsstamma-i-xvivo-perfusion-ab-publ\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.xvivogroup.com\/us\/pressreleases\/rattelse-av-kallelse-till-arsstamma-i-xvivo-perfusion-ab-publ\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/rattelse-av-kallelse-till-arsstamma-i-xvivo-perfusion-ab-publ\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.xvivogroup.com\/us\/"},{"@type":"ListItem","position":2,"name":"R\u00c4TTELSE AV KALLELSE TILL \u00c5RSST\u00c4MMA I XVIVO PERFUSION AB (publ)"}]},{"@type":"WebSite","@id":"https:\/\/www.xvivogroup.com\/us\/#website","url":"https:\/\/www.xvivogroup.com\/us\/","name":"United States","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.xvivogroup.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news\/2929","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/media?parent=2929"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}